As of 2026-04-01, the EV/EBITDA ratio of Coherus BioSciences Inc (CHRS) is -1.24. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. CHRS's latest enterprise value is 215.51 mil USD. CHRS's TTM EBITDA according to its financial statements is -174.40 mil USD. Dividing these 2 quantities gives us the above CHRS EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 6.1x - 11.8x | 8.0x |
| Forward P/E multiples | 7.5x - 15.1x | 11.7x |
| Fair Price | (8.52) - (13.52) | (11.21) |
| Upside | -604.2% - -900.2% | -763.2% |
| Date | EV/EBITDA |
| 2026-03-24 | -1.25 |
| 2026-03-23 | -1.19 |
| 2026-03-20 | -1.09 |
| 2026-03-19 | -1.17 |
| 2026-03-18 | -1.14 |
| 2026-03-17 | -1.23 |
| 2026-03-16 | -1.21 |
| 2026-03-13 | -1.18 |
| 2026-03-12 | -1.24 |
| 2026-03-11 | -1.31 |
| 2026-03-10 | -1.46 |
| 2026-03-09 | -1.44 |
| 2026-03-06 | -1.35 |
| 2026-03-05 | -1.30 |
| 2026-03-04 | -1.30 |
| 2026-03-03 | -1.20 |
| 2026-03-02 | -1.20 |
| 2026-02-27 | -1.22 |
| 2026-02-26 | -1.24 |
| 2026-02-25 | -1.23 |
| 2026-02-24 | -1.22 |
| 2026-02-23 | -1.18 |
| 2026-02-20 | -1.18 |
| 2026-02-19 | -1.25 |
| 2026-02-18 | -1.18 |
| 2026-02-17 | -1.17 |
| 2026-02-13 | -1.17 |
| 2026-02-12 | -1.51 |
| 2026-02-11 | -1.54 |
| 2026-02-10 | -1.60 |
| 2026-02-09 | -1.55 |
| 2026-02-06 | -1.62 |
| 2026-02-05 | -1.58 |
| 2026-02-04 | -1.69 |
| 2026-02-03 | -1.69 |
| 2026-02-02 | -1.65 |
| 2026-01-30 | -1.64 |
| 2026-01-29 | -1.79 |
| 2026-01-28 | -1.69 |
| 2026-01-27 | -1.94 |
| 2026-01-26 | -1.74 |
| 2026-01-23 | -1.55 |
| 2026-01-22 | -1.15 |
| 2026-01-21 | -1.19 |
| 2026-01-20 | -1.12 |
| 2026-01-16 | -1.16 |
| 2026-01-15 | -1.21 |
| 2026-01-14 | -1.16 |
| 2026-01-13 | -1.24 |
| 2026-01-12 | -1.20 |